Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F12%3A33141661" target="_blank" >RIV/61989592:15310/12:33141661 - isvavai.cz</a>

Výsledek na webu

<a href="http://benthamscience.com/contents-JCode-MRMC-Vol-00000012-Iss-00000012.htm" target="_blank" >http://benthamscience.com/contents-JCode-MRMC-Vol-00000012-Iss-00000012.htm</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells

Popis výsledku v původním jazyce

The idea of "repurposing" of existing drugs provides an effective way to develop and identify new therapies. Disulfiram (Antabuse), a drug commonly used for the treatment of alcoholism, shows promising anticancer activity in both preclinical and clinicalstudies. In the human body, disulfiram is rapidly converted to its reduced metabolite, diethyldithiocarbamate. If copper ions are available, a bis(diethyldithiocarbamate)-copper(II) complex is formed. Disulfiram's selective anticancer activity is attributed to the copper(II) complex's ability to inhibit the cellular proteasome. It is assumed that the complex inhibits the proteasome by a mechanism that is distinct to the clinically used drug bortezomib, targeting the 19S rather than the 20S proteasome.This difference could be explained by inhibition of the JAMM domain of the POH1 subunit within the lid of the 19S proteasome.

Název v anglickém jazyce

Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells

Popis výsledku anglicky

The idea of "repurposing" of existing drugs provides an effective way to develop and identify new therapies. Disulfiram (Antabuse), a drug commonly used for the treatment of alcoholism, shows promising anticancer activity in both preclinical and clinicalstudies. In the human body, disulfiram is rapidly converted to its reduced metabolite, diethyldithiocarbamate. If copper ions are available, a bis(diethyldithiocarbamate)-copper(II) complex is formed. Disulfiram's selective anticancer activity is attributed to the copper(II) complex's ability to inhibit the cellular proteasome. It is assumed that the complex inhibits the proteasome by a mechanism that is distinct to the clinically used drug bortezomib, targeting the 19S rather than the 20S proteasome.This difference could be explained by inhibition of the JAMM domain of the POH1 subunit within the lid of the 19S proteasome.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE.2.3.20.0062" target="_blank" >EE.2.3.20.0062: Levný lék antabus jako protinádorové léčivo: mechanismus účinku a klinické testy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mini - Reviews in Medicinal Chemistry

ISSN

1389-5575

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

9

Strana od-do

1184-1192

Kód UT WoS článku

000309058100003

EID výsledku v databázi Scopus

—